Results 241 to 250 of about 135,666 (308)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Prosocial helping behaviors attenuate accelerated cognitive decline driven by APOE ε4. [PDF]

Alzheimers Dement
Han SH, Faul JD.
europepmc   +1 more source

Vom begriff des ''commercium''

Kaser , Max, Kaser , Max
openaire   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

The second `'sacred disease'': Earlier euphemistic equivalent of `'Hansen's disease''

, 1996
openaire   +1 more source

Rifaximin ameliorates memory impairment and Alzheimer's pathological changes in APP/PS1 mice associated with changes in the gut microbiome–bile acids–serum metabolites networks

British Journal of Pharmacology, EarlyView.
Background and Purpose Modifying the brain–gut–microbiota axis has emerged as a promising therapeutic strategy against Alzheimer's disease (AD). Whether rifaximin, a non‐absorbed and non‐systemic antibiotic, can be applied to the treatment of AD remains unexplored.
Di Wu, Mei‐Tong Nie, Jixian Lin, Yang Liu, Yong Wang, Min Chu, Lan Zheng, Jing Zhao   +7 more
wiley   +1 more source

APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers's disease. [PDF]

Nat Genet
Thomassen JQ, Leonard H, Ulms B, Grenier-Boley B, Heikkinen S, Garcia-González P, Castillo-Morales A, Kikuchi M, Gim J, Cao H, Küçükali F, Amin N, Yoon D, de Rojas I, Alvarez Jerez P, Alvarez V, Arosio B, Bellenguez C, Bergh S, Billingsley K, Blauwendraat C, Boada M, Borroni B, Bossù P, Bullido MJ, Daniele A, Carracedo Á, de Mendonça A, Cookson M, Deckert J, Dichgans M, Djurovic S, Dols-Icardo O, Dufouil C, Düzel E, Escott-Price V, Fladby T, Fratiglioni L, Fu AKY, Galimberti D, García-Alberca JM, Giedraitis V, Garcia-Ribas G, Graff C, Grimmer T, Grünblatt E, Hanon O, Hausner L, Heilmann-Heimbach S, Hort J, Jessen F, Jensen K, Jonson C, Kim Y, Kuznetsov N, Leinonen V, Lipponen A, Luo J, Makarious M, Martiskainen H, Masullo C, Mecocci P, Mehrabian S, Mir P, Miyashita A, Moebus S, Mok KY, Molina Porcel L, Moreno F, Nacmias B, Parnetti L, Pastor P, Pérez-Tur J, Peters O, Pijnenburg YAL, Piñol-Ripoll G, Popp J, Rainero I, Real LM, Riedel-Heller S, Rodriguez-Rodriguez E, Rongve A, Rossi G, Royo JL, Rujescu D, Saltvedt I, Sáez ME, Sánchez-Valle R, Sanchez-Garcia F, Sandau N, Scarmeas N, Scheffler K, Scherbaum N, Schneider A, Selbæk G, Seripa D, Solfrizzi V, Spallazzi M, Squassina A, Stordal E, Tesi N, Tremolizzo L, Tripathi KP, van der Flier WM, Williams J, Wiltfang J, Aarsland D, Singleton AB, Amouyel P, Debette S, Tsolaki M, Nicolas G, van der Lee S, Holstege H, Fernandez MV, Kehoe PG, Sleegers K, Ingelsson M, Ghidoni R, Andreassen OA, Holmans PA, Sánchez-Juan P, Sims R, Ip NY, Lee KH, Ikeuchi T, Ramirez A, Ruiz A, Hiltunen M, Lambert JC, van Duijn C, Nalls M, Frikke-Schmidt R.   +132 more
europepmc   +1 more source

Targeted delivery of the CB2 receptor agonist JWH‐133 via VCAM‐1‐functionalised nanoparticles attenuates atherosclerosis and reveals sex‐specific therapeutic outcomes

British Journal of Pharmacology, EarlyView.
Background and Purpose Atherosclerosis, a chronic inflammatory disease characterised by lipid accumulation and endothelial dysfunction, remains a leading cause of cardiovascular morbidity and mortality. While cannabinoid 2 (CB2) receptor agonists show therapeutic promise in preclinical studies, their systemic application is hindered by poor ...
Lucía Martín‐Navarro, Lucía Martín‐Banderas, Josefa Álvarez‐Fuentes, María Dolores Herrera‐González   +3 more
wiley   +1 more source